Clinical trials referenced in this document:
Funding for this research was provided by:
teijin pharma ltd
Received: 25 July 2021
Accepted: 10 January 2022
First Online: 25 February 2022
: This study was approved by the institutional review boards of each of the six participating institutions. This study was conducted in accordance with the tenets of the Declaration of Helsinki, and all participants in this study provided written informed consent before their inclusion in the research.
: Not applicable.
: TT reports personal fees from Teijin Pharma. KT reports personal fees from Teijin Pharma. OY reports that he has not received any fee or non-financial support from any organization. HK reports personal fees from Teijin Pharma. KH reports non-financial support from Teijin Pharma. KD reports personal fees and non-financial support from Teijin Pharma.